ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

• Status: Completed
• Trial end date: 2009-06-01

Summary

The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.

• Phase: Phase 3

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole; Tamoxifen